2013
DOI: 10.1016/j.bone.2013.04.007
|View full text |Cite
|
Sign up to set email alerts
|

Severe neuronopathic autosomal recessive osteopetrosis due to homozygous deletions affecting OSTM1

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1
1

Citation Types

4
21
1

Year Published

2014
2014
2022
2022

Publication Types

Select...
9
1

Relationship

1
9

Authors

Journals

citations
Cited by 23 publications
(26 citation statements)
references
References 35 publications
4
21
1
Order By: Relevance
“…In individuals who carry the FUT2 p.Trp154* variant, there is lower expression of OSTM1 (MIM: 607649). In humans, OSTM1 mutations cause autosomal-recessive, rare, severe osteopetrosis (MIM: 259720), a condition characterized by reduced osteoclast number and activity, bony sclerosis, fractures, reduced bone marrow cavities, pancytopenia, recurrent infections, and early death, 40 consistent with hematopoietic and osteoclast defects in gl/Ostm1-mutant mice. 41 Since we identified individuals with FUT2 stop variants with cholesteatomas and/or downregulated OSTM1 expression, reduced FUT2 levels might play a role in cholesteatoma formation and bone pathology in part via decreased OSTM1 levels.…”
Section: Discussionmentioning
confidence: 99%
“…In individuals who carry the FUT2 p.Trp154* variant, there is lower expression of OSTM1 (MIM: 607649). In humans, OSTM1 mutations cause autosomal-recessive, rare, severe osteopetrosis (MIM: 259720), a condition characterized by reduced osteoclast number and activity, bony sclerosis, fractures, reduced bone marrow cavities, pancytopenia, recurrent infections, and early death, 40 consistent with hematopoietic and osteoclast defects in gl/Ostm1-mutant mice. 41 Since we identified individuals with FUT2 stop variants with cholesteatomas and/or downregulated OSTM1 expression, reduced FUT2 levels might play a role in cholesteatoma formation and bone pathology in part via decreased OSTM1 levels.…”
Section: Discussionmentioning
confidence: 99%
“…Children with malignant infantile osteopetrosis (MIOP), the lethal form of OP, exhibit an array of symptoms including pancytopenia, defective bone metabolism, and neurologic abnormalities such as progressive blindness, seizures, and eventual death if untreated; symptoms are secondary to both bony overgrowth and direct neurotoxicity. [1][2][3][4][5][6][7] To date, mutations in 12 genes have been associated with the OP phenotype, most commonly in the TCIRG1 (50%), CLCN7 (15%), 8,9 and OSTM1 (5%) genes. 2,3 Although the average lifespan for a patient with MIOP is 5 to 6 years of age, patients specifically with OSTM1 mutations display a more severe, intrinsic neurodegenerative process, and death generally occurs earlier, between 0 and 2 years of age.…”
Section: Introductionmentioning
confidence: 99%
“…The neuronal complications have been secondarily ascribed to abnormal bone accumulation in osteopetrosis that compresses cranial nerves, resulting in optic atrophy and blindness as well as hearing impairment (2). However, there is recent evidence for primary central nervous system (CNS) defects in osteopetrotic patients with OSTM1 and ClC7 mutations (3)(4)(5)(6)(7). Of interest, OSTM1 mutations lead to both more severe osteopetrosis and CNS defects (8,9).…”
mentioning
confidence: 99%